Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 17/20 | 0.80 |
| ▸ | GABRB2 | P47870 | 17/20 | 0.80 |
| ▸ | MLYCD | O95822 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780987 | 0.90 | GABRA2 (0.85) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL5784967 | 0.83 | GABRA2 (0.57) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL13437647 | 0.82 | GABRA2 (0.95) | GABRA2GABRB2MLYCDPTGS2TARBP2 | |
| SCHEMBL5784917 | 0.82 | GABRA2 (0.71) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL23027867 | 0.82 | GABRA2 (1.00) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL5423251 | 0.81 | GABRA2 (0.88) | GABRA2GABRB2MLYCDPTGS2TARBP2 | |
| SCHEMBL2152521 | 0.80 | GABRA2 (0.75) | GABRA2GABRB2 | |
| SCHEMBL2942875 | 0.80 | MLYCD (1.00) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL5782631 | 0.79 | GABRA2 (0.67) | GABRA2GABRB2MLYCDPTGS2 | |
| SCHEMBL13437646 | 0.79 | GABRA2 (0.83) | GABRA2GABRB2MLYCDPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| EP-1621537-A1 | FIVE-MEMBERED HETEROCYCLIC DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | GABRA2 3363/4885GABRB2 3006/4885MLYCD 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.